Akshay Vaishnaw Biography and Net Worth

President, R&D of Scholar Rock

Dr. Akshay Vaishnaw has served as President of R&D of Scholar Rock since April 2025. Prior, he served as a member of Scholar Rock’s board of directors from May 2019 until April 2025. He is a venture partner with over 25 years of experience in the biotechnology industry. Since 2006, he served in positions of increasing responsibility across Research and Development (R&D) at Alnylam Pharmaceuticals, and most recently served as President of Alnylam Pharmaceuticals. Previously, Akshay held various positions in clinical research and business development at Biogen.

He is a board member Hemab and the non-profit, TB Alliance. Previously, he served on the Boards of Visterra, Inc, and Editas Medicine Inc.

Akshay received a bachelor’s degree from University College Cardiff, UK, an MD from the University of Wales College of Medicine, UK, and a PhD from the University of London, UK, in Molecular Immunology. He is a Fellow of the Royal College of Physicians, UK.

What is Akshay Vaishnaw's net worth?: The estimated net worth of Akshay Vaishnaw is at least $27.81 million as of May 29th, 2025. Dr. Vaishnaw owns 616,205 shares of Scholar Rock stock worth more than $27,808,715 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Vaishnaw may own. Learn More about Akshay Vaishnaw's net worth.
How do I contact Akshay Vaishnaw?: The corporate mailing address for Dr. Vaishnaw and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Akshay Vaishnaw's contact information.
Has Akshay Vaishnaw been buying or selling shares of Scholar Rock?: Akshay Vaishnaw has not been actively trading shares of Scholar Rock in the last ninety days. Most recently, Akshay Vaishnaw sold 6,750 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.72, for a transaction totalling $200,610.00. Following the completion of the sale, the insider now directly owns 616,205 shares of the company's stock, valued at $18,313,612.60. Learn More on Akshay Vaishnaw's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 10/6/2025.

Akshay Vaishnaw Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/29/2025	Sell	6,750	$29.72	$200,610.00	616,205

Akshay Vaishnaw Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $45.20

$42.83

$45.50

50 Day Range

MA: $34.97

$27.92

$45.20

2 Week Range

Now: $45.20

$22.71

$46.98

Volume

1,340,235 shs

Average Volume

2,069,553 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61